A phase II open label study investigating the activity of diflomotecan (BN80915) administered at the fixed dose of 7mg as a 20 minute intravenous infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) who have failed first-line treatment with a platinum based regimen
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Diflomotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2005 New trial record.